Experience with Linezolid for the Treatment of Rifampin-Susceptible Tuberculosis in San Francisco
Linezolid is recommended for the treatment of rifampin-resistant tuberculosis (TB), but its role in rifampin-susceptible TB (RS-TB) is less understood. In 45 RS-TB patients treated with linezolid, 8 stopped due to adverse events, most commonly cytopenias. Further research is needed on linezolid efficacy, dosing, and adverse event management in RS-TB.
Authors
- John D. Szumowski (ORCID: https://orcid.org/0000-0002-0287-9704)
- Allison L. Phillips (ORCID: https://orcid.org/0000-0002-0192-5190)
- Gustavo E. Velásquez (ORCID: https://orcid.org/0000-0003-1438-0692)
- Janice K. Louie (ORCID: https://orcid.org/0000-0001-6568-5213)
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- San Francisco Department of Public Health (US)
- Global Brain Health Institute (US)
- Global Solutions for Infectious Diseases (US)
- University of San Francisco (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1093/ofid/ofaf714
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00